RBDCOV |EMA starts rolling review of HIPRA COVID-19 vaccine

April 8, 2022

EMA’s human medicines committee (CHMP) has started a rolling review of COVID-19 HIPRA vaccine. A rolling review is a regulatory tool that the EMA uses to expedite the assessment of a promising medicine or vaccine during a public health emergency.

The CHMP decision to initiate continuing review is based on preclinical development and preliminary results from clinical trials. Preliminary results show that the immune response is effective against SARS-CoV-2, including variants of concern such as Omicron.

The purpose behind RBDCOV project is to offer a new tool to control the pandemic at short-medium and long term, and to manufacture and test the first recombinant protein-based vaccine to be authorised in Europe.

RBDCOV is a EU-funded vaccine-focused research project that brings together the expertise of several European groups and companies in rational design of animal and human vaccine immunogens, vaccine manufacturing, distribution and commercialisation, cellular and humoral immune responses, clinical trials, regulatory issues, stakeholders’ involvement and patients’ perspective. Asphalion is proud Regulatory partner of the project.

Check the complete new here:

EMA starts rolling review of HIPRA COVID-19 vaccine – RBDCOV

 

 

Search News & Events

  • Filter by category

Share

Related news and events

RBDCOV | 14-months follow-up meeting

The second face-to-face RBDCOV meeting is taking place today at Palau Macaya in Barcelona! Our expert, Chris Mann, is attending the meeting in person. After

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting